Hydrogen gas (H2) delivered by intraperitoneal injection alleviated methionine- and choline-deficient diet-induced metabolic dysfunction-associated steatotic liver disease in mice via inhibiting GSDMD- and GSDME-mediated pyroptosis.
Yun Chen, Kangrong Wang, Wenhai Guo, Chengqin Lu, Wenting Suo, Qiuling Li, Yao Deng, Xinling Chen, Min Dai, Xiaodong Zhang, Jiean Xu, Wen Su, Shuangling Yang, Hongzhi Yang, Fuman Yan, Haimei Liu, Yaxing Zhang · Frontiers in pharmacology · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, among these, Acaca, Fasn, and CD36 were decreased ( Figures 2G-I ), while Mttp and Apob were increased by high dose H₂ therapy ( Figures 2N,O ). These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in mice. Among these, Acaca, Fasn, and CD36 were decreased ( Figures 2G-I ), while Mttp and Apob were increased by high dose H₂ therapy ( Figures 2N,O ).
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Insert the syringe needle into the evacuated plastic infusion bottle (100 mL), then further loosen the pressure reducing valve and introduce H₂ into the infusion bottle until there is no dead volume. (B) H₂-rich medium was prepared by introducing H₂ into the infusion bottle containing 10 mL DMEM until there is no dead volume, then, it was stored in 4°C for 6 h before used. (C) The experimental procedure is as follows. Animals in H₂ treatment group are intraperitoneally injected with H₂ once a day at 5:00 p.m. since the eighth day. On day eighth, mice were daily given H₂ by intraperitoneal injection at the doses of 0.5 mL/100 g for MCD + H₂ (L) group, and 1.0 mL/100 g for MCD + H₂ (H) group. H₂-rich DMEM with 1% FBS was added to the OA+H₂ and H₂ groups, and the Control group and OA group were treated with the same volume of H₂ -free DMEM with 1% FBS. Among these, Acaca, Fasn, and CD36 were decreased ( Figures 2G-I ), while Mttp and Apob were increased by high dose H₂ therapy ( Figures 2N,O ). The authors concluded that H₂ is an anti-pyroptosis gas molecule, intraperitoneal injection of H₂ is a novel therapeutic strategy for MASLD that deserves further investigation. Hydrogen gas (H₂), which is the lightest and diffusible gas molecule, has strong abilities to alleviate excessive oxidative stress, inflammation, and apoptosis.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment. The hydrogen delivery method was inhaled hydrogen gas.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.